Double-digit growth for pharmaceutical firm’s parent company
STADA Arzneimittel AG, the listed parent company of Huddersfield-based pharmaceutical business Thornton & Ross, has published its annual results and reported a 12% growth in group sales to €2.61bn (£2.3bn).
STADA has also recorded a 24% rise in adjusted EBITDA to €625.5m (£557.3m) in its 2019 year-end results.
The Germany-based Group’s progress included strong organic sales growth of 8%.
STADA CEO, Peter Goldschmidt, said: “These outstanding results are enabling us to accelerate our investment not only in our own product development but also broadly into external co-development and product in-licensing. This supports our sustainability and long-term growth as we continue to build the best team in the industry.
“As a preferred partner, STADA signed more than 50 licensing deals during 2019, including in prospective high-growth areas such as biosimilars.
“During 2019, we showed agility to gain market share from our competitors in all major European markets. Based on the outstanding results achieved by our industry-leading team, we will be able to continue our entrepreneurial growth journey and position STADA as the go-to-partner for generics and consumer healthcare.”
“Double-digit sales growth in 2019 is a testament to the dedication and expertise of our UK workforce,” added STADA’s executive vice president, Roger Scarlett-Smith. “The UK remains firmly within STADA’s top-five national markets by turnover.”
Thornton & Ross manufactures and supplies a wide range of branded over-the-counter medicines, dermatological solutions and other healthcare and hygiene products including Zoflora®, Hedrin® and Setlers®.
It has a strong track record of supplying the NHS with emollients and bone health products, as well as offering a diverse portfolio of generic pharmaceuticals.
